- Affirms full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91, reflecting growth of 7% to 10% over full-year 2021 GAAP diluted EPS and growth of 5% to 9% over full-year 2021 non-GAAP diluted EPS
INmune Bio Inc. Announces Approval Of Clinical Trial Application By The U.K. Medicines And Healthcare Products Regulatory Agency For Phase 2 Clinical Trial In Alzheimer’s Disease
The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro™ in patients with early Alzheimer's disease to the U.K.
Boca Raton, Florida,
